Coinfection with hepatitis B virus (HBV) and HIV is common, however there are few data on the influence of resolved HBV infection (i.e. HBcAb+/HBsAg- serology) on clinical progression of infection during antiretroviral therapy (ART).
HIV+ patients (pts) enrolled from the ICONA Foundation Study Cohort were prospectively evaluated to investigate the influence of resolved HBV infection (HBcAb+) on the risk of occurrence of advanced liver fibrosis (defined as Fibrosis-4 score[FIB-4]>3.25). We included pts free from liver fibrosis (FIB-4 <3.25) at the date of their first available serology test (baseline). We distinguished 3 subgroups according to HBV serology at baseline: HBsAg+, HBsAg-/HBcAb+ (HBcAb+) and HBsAg-/HBcAb- (HBV-) pts. Standard survival analysis by means of Kaplan-Meier curves and Cox regression models with time-fixed covariates measured at baseline was performed. A Poisson regression was also performed to evaluate the same associations after stratifying for ART regimen currently used (grouped as XTC/TDF-based vs. not).
2,528/8,880 pts (29%) HBcAb+ were identified: mainly males (75%) the majority having acquired HIV through sexual contacts (78%). With respect to HBV-, a significant higher proportion of HBcAb+ and HBsAg+ (12% and 14% vs. 9%, p<.001) pts had an AIDS event at baseline and a significant lower median number of CD4 cell nadir (315 and 330 vs 365, p<.001). Overall, 199 pts experienced a FIB-4 progression >3.25, among them 107/2528 HBcAb+ pts (4%), compared to 71/5907 HBV- (1%) and 21/445 HBsAg+ pts (5%). The estimated 10-year risk of death was 4.2 (95% CI:3.4-5.1) months in HBV- pts, 7.6 (5.9-9.2) in HBcAb+ and 14.1 (8.1-20.0) in HBsAg+ pts (log-rank p-value <0.0001). Compared to HBV- subjects, an increased risk of develop a FIB-4 >3,25 was shown in HBcAb+ (1.49,95%CI 1.03-2.15, p=0.035) and HBsAg+ subjects (2.62,95%CI 1.51-4,55, p<.001, Table). There was evidence that the difference in risk between HBcAb+ and HBV- was a lot larger in people currently not receiving a XTC/TDF-based ART (adjusted RR: 20.8 (95%: 2.94;147), interaction p-value =0.04).
HBcAb+(HBsAg-)/HIV+ pts showed a significantly higher risk of progression to liver fibrosis compared to HBV- pts, especially in those not receiving anti-HBV drugs. These findings suggest that HBV resolved infection should be monitored as it is an indicator of faster hepatic disease evolution in HBV/HIV coinfected pts.